The star 1-1-42 （=vZ1390）, a cluster member in M3, located near the red edge of the instability strip of the horizontal branch, was discovered by Roberts and Sandage as a low amplitude variable, it was designated as...The star 1-1-42 （=vZ1390）, a cluster member in M3, located near the red edge of the instability strip of the horizontal branch, was discovered by Roberts and Sandage as a low amplitude variable, it was designated as V204 in the ＂second catalogue of variable stars in globular clusters＂, but its coordinates given in all versions of this catalogue are wrong since 1955. We argue that V204 is indeed a low amplitude HB variable star, located near to the red edge of the instability strip, with a period of 0.74785d and an amplitude of about 0.04 mag in V. We also find that the red cluster member star 1-1-39 is a low amplitude variable with a period of 1.16^d and amplitude of about 0.03 mag in V which might be pulsating at the second overtone.展开更多
Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance afte...Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL 180M/M204V mutation (41.28%), 28patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.展开更多
文摘The star 1-1-42 （=vZ1390）, a cluster member in M3, located near the red edge of the instability strip of the horizontal branch, was discovered by Roberts and Sandage as a low amplitude variable, it was designated as V204 in the ＂second catalogue of variable stars in globular clusters＂, but its coordinates given in all versions of this catalogue are wrong since 1955. We argue that V204 is indeed a low amplitude HB variable star, located near to the red edge of the instability strip, with a period of 0.74785d and an amplitude of about 0.04 mag in V. We also find that the red cluster member star 1-1-39 is a low amplitude variable with a period of 1.16^d and amplitude of about 0.03 mag in V which might be pulsating at the second overtone.
文摘Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL 180M/M204V mutation (41.28%), 28patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.
